A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer-Reference-Cited by-同舟云学术

A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer

Published:2016-06-01 Issue:6 Volume:46 Page:517-521
ISSN:1465-3621
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Morimoto Akemi¹,Nagao Shoji¹,Kogiku Ai¹,Yamamoto Kasumi¹,Miwa Maiko¹,Wakahashi Senn¹,Ichida Kotaro¹,Sudo Tamotsu¹,Yamaguchi Satoshi¹,Fujiwara Kiyoshi¹

Affiliation:

1. Department of Gynecologic Oncology, Hyogo Cancer Center, Akashi, Hyogo, Japan

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/46/6/517/26443724/hyw029.pdf

Reference12 articles.

1. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT);Chi;Gynecol Oncol,2012

2. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study;Eisenkop;Gynecol Oncol,1998

3. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial;Crawford;J Clin Oncol,2005

4. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for research and Treatment of Cancer;van der Burg;N Engl J Med,1995

5. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer;Vergote;N Engl J Med,2010

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utility of CA-125 in interval surgery;Obstetrics & Gynecology International Journal;2024-04-01

2. Systematic Review of the Survival Outcomes of Neoadjuvant Chemotherapy in Women with Malignant Ovarian Germ Cell Tumors;Cancers;2023-09-08

3. Preoperative Cancer Antigen 125 Level as Predictor for Complete Cytoreduction in Ovarian Cancer: A Prospective Cohort Study and Systematic Review;Cancers;2022-11-22

4. Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction;Diagnostics;2022-04-14

5. Correlation Between Clinical Outcomes and Serum CA-125 Levels After Standard Treatment for Epithelial Ovarian Cancer;Anticancer Research;2021-12-29